论文部分内容阅读
目的:应用淋巴管内皮细胞抗体D2-40单克隆抗体(mab)检测乳腺导管癌演变中淋巴管密度(LVD)变化。方法:选取乳腺不典型导管增生(ADH)、导管内癌(DCIS)和微浸润癌(MDC)各20例,浸润性导管癌(IDC)50例,采用免疫组织化学SP法检测各组的D2-40表达,光镜下选择3个淋巴管丰富区域,并在200倍视野下进行LVD计数。结果:D2-40标记的LVD在乳腺ADH、DCIS、MDC及IDC瘤周中分别为5.00±1.78、5.35±1.98、5.80±2.71和14.62±3.48,差异有统计学意义,P<0.05。进一步行LSD检验发现,ADH、DCIS和MDC 3组间差异无统计学意义,P>0.05。结论:在直至MDC阶段,乳腺癌通过淋巴管转移的风险低;但IDC阶段,D2-40标记的LVD显著增加、转移风险增加以及LVD的多少可能成为鉴别乳腺癌微浸润还是浸润的参考指标,为乳腺癌脉管转移的预防和治疗时机选择提供相关理论依据。
OBJECTIVE: To detect the changes of lymphatic vessel density (LVD) in ductal carcinoma of the breast using the lymphatic endothelial cell antibody D2-40 monoclonal antibody (mab). Methods: 20 cases of atypical ductal hyperplasia (ADH), ductal carcinoma (DCIS) and micro-invasive carcinoma (MDC) were selected and 50 cases of invasive ductal carcinoma (IDC) were selected. Immunohistochemistry was used to detect the expression of D2 -40 expression, light microscope, select three areas rich in lymphatic vessels, and at 200 times the field of vision LVD count. Results: The LVD D2-40 labeled in the mammary gland was 5.00 ± 1.78, 5.35 ± 1.98, 5.80 ± 2.71 and 14.62 ± 3.48 in ADH, DCIS, MDC and IDC respectively. The difference was statistically significant (P <0.05). Further line LSD test found no significant difference between ADH, DCIS and MDC 3 groups, P> 0.05. CONCLUSIONS: The risk of breast cancer metastasis through lymphatic vessels is low until MDC stage. However, in IDC stage, the marked increase of D2-40 marked LVD, the increased risk of metastasis and the number of LVD may become a reference index to differentiate micro-infiltration or infiltration of breast cancer. To provide a theoretical basis for the timing of the prevention and treatment of breast cancer vascular metastasis.